Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia Aziz NazhaMrinal M. Patnaik Myelodysplastic Syndromes (M Savona, Section Editor) 31 July 2018 Pages: 341 - 347
Updates on Circulating Tumor DNA Assessment in Lymphoma Justin M. DarrahAlex F. Herrera B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 23 August 2018 Pages: 348 - 355
Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma Joanna RhodesDaniel J. Landsburg B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 15 August 2018 Pages: 356 - 368
Emerging EZH2 Inhibitors and Their Application in Lymphoma Jennifer K. LueJennifer E. Amengual B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 15 August 2018 Pages: 369 - 382
Strategies for Predicting Response to Checkpoint Inhibitors Roberta ZappasodiJedd D. WolchokTaha Merghoub CART and Immunotherapy (M Ruella, Section Editor) 29 August 2018 Pages: 383 - 395
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease Katherine C. PehlivanBrynn B. DuncanDaniel W. Lee Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors) 17 August 2018 Pages: 396 - 406
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis John H. BairdJason Gotlib Myeloproliferative Neoplasms (B Stein, Section Editor) 28 August 2018 Pages: 407 - 416